Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Biochem Mol Toxicol ; 15(3): 143-9, 2001.
Article in English | MEDLINE | ID: mdl-11424224

ABSTRACT

In light of evidence that some complications of diabetes mellitus may be caused or exacerbated by oxidative damage, we investigated the effects of subacute treatment with the antioxidant quercetin on tissue antioxidant defense systems in streptozotocin-induced diabetic Sprague-Dawley rats (30 days after streptozotocin induction). Quercetin, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, was administered at a dose of 10mg/kg/day, ip for 14 days, after which liver, kidney, brain, and heart were assayed for degree of lipid peroxidation, reduced and oxidized glutathione content, and activities of the free-radical detoxifying enzymes catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase. Treatment of normal rats with quercetin increased serum AST and increased hepatic concentration of oxidized glutathione. All tissues from diabetic animals exhibited disturbances in antioxidant defense when compared with normal controls. Quercetin treatment of diabetic rats reversed only the diabetic effects on brain oxidized glutathione concentration and on hepatic glutathione peroxidase activity. By contrast, a 20% increase in hepatic lipid peroxidation, a 40% decline in hepatic glutathione concentration, an increase in renal (23%) and cardiac (40%) glutathione peroxidase activities, and a 65% increase in cardiac catalase activity reflect intensified diabetic effects after treatment with quercetin. These results call into question the ability of therapy with the antioxidant quercetin to reverse diabetic oxidative stress in an overall sense.


Subject(s)
Catalase/metabolism , Diabetes Mellitus, Experimental/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Quercetin/pharmacology , Superoxide Dismutase/metabolism , Animals , Antioxidants/metabolism , Brain/metabolism , Catalase/chemistry , Glutathione/metabolism , Kidney/metabolism , Lipid Peroxidation/drug effects , Liver/metabolism , Male , Molecular Structure , Myocardium/metabolism , Rats , Rats, Sprague-Dawley , Thiobarbituric Acid Reactive Substances
2.
J Biochem Mol Toxicol ; 15(3): 159-64, 2001.
Article in English | MEDLINE | ID: mdl-11424226

ABSTRACT

Because some complications of diabetes mellitus may result from oxidative damage, we investigated the effects of subacute treatment (10mg/kg/day, intraperitoneal [ip], for 14 days) with the antioxidant isoeugenol on the oxidant defense system in normal and 30-day streptozotocin-induced diabetic Sprague-Dawley rats. Liver, kidney, brain, and heart were assayed for degree of lipid peroxidation, reduced and oxidized glutathione content, and activities of the free radical-detoxifying enzymes catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase. All tissues from diabetic animals exhibited disturbances in antioxidant defense when compared with normal controls. Treatment with isoeugenol reversed diabetic effects on hepatic glutathione peroxidase activity and on oxidized glutathione concentration in brain. Treatment with the lipophilic compound isoeugenol also decreased lipid peroxidation in both liver and heart of normal animals and decreased hepatic oxidized glutathione content in both normal and diabetic rats. Some effects of isoeugenol treatment, such as decreased activity of hepatic superoxide dismutase and glutathione reductase in diabetic rats, were unrelated to the oxidative effects of diabetes. In heart of diabetic animals, isoeugenol treatment resulted in an exacerbation of already elevated activities of catalase. These results indicate that isoeugenol therapy may not reverse diabetic oxidative stress in an overall sense.


Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Experimental/metabolism , Eugenol/pharmacology , Glutathione/metabolism , Oxidative Stress/drug effects , Animals , Brain/drug effects , Brain/metabolism , Catalase/metabolism , Eugenol/analogs & derivatives , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Molecular Structure , Myocardium/metabolism , Oxidative Stress/physiology , Rats , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism
3.
J Biochem Mol Toxicol ; 15(1): 41-6, 2001.
Article in English | MEDLINE | ID: mdl-11170314

ABSTRACT

Coenzyme Q10 is an endogenous lipid soluble antioxidant. Because oxidant stress may exacerbate some complications of diabetes mellitus, this study investigated the effects of subacute treatment with exogenous coenzyme Q10 (10 mg/kg/day, i.p. for 14 days) on tissue antioxidant defenses in 30-day streptozotocin-induced diabetic Sprague-Dawley rats. Liver, kidney, brain, and heart were assayed for degree of lipid peroxidation, reduced and oxidized glutathione contents, and activities of catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase. All tissues from diabetic animals exhibited increased oxidative stress and disturbances in antioxidant defense when compared with normal controls. Treatment with the lipophilic compound coenzyme Q10 reversed diabetic effects on hepatic glutathione peroxidase activity, on renal superoxide dismutase activity, on cardiac lipid peroxidation, and on oxidized glutathione concentration in brain. However, treatment with coenzyme Q10 also exacerbated the increase in cardiac catalase activity, which was already elevated by diabetes, further decreased hepatic glutathione reductase activity, augmented the increase in hepatic lipid peroxidation, and further increased glutathione peroxidase activity in the heart and brain of diabetic animals. Subacute dosing with coenzyme Q10 ameliorated some of the diabetes-induced changes in oxidative stress. However, exacerbation of several diabetes-related effects was also observed.


Subject(s)
Antioxidants/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Ubiquinone/therapeutic use , Animals , Antioxidants/administration & dosage , Brain/drug effects , Brain/metabolism , Catalase/metabolism , Coenzymes , Diabetes Mellitus, Experimental/chemically induced , Glutathione/metabolism , Heart/drug effects , Injections, Intraperitoneal , Kidney/drug effects , Kidney/metabolism , Lipid Peroxidation/drug effects , Liver/drug effects , Liver/metabolism , Male , Myocardium/metabolism , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Streptozocin , Superoxide Dismutase/metabolism , Ubiquinone/administration & dosage , Ubiquinone/analogs & derivatives
4.
J Biochem Mol Toxicol ; 14(6): 329-34, 2000.
Article in English | MEDLINE | ID: mdl-11083086

ABSTRACT

Using diabetes mellitus as a model of oxidative damage, this study investigated whether subacute treatment (10 mg/kg/day, intraperitoneally for 14 days) with the compound piperine would protect against diabetes-induced oxidative stress in 30-day streptozotocin-induced diabetic Sprague-Dawley rats. Liver, kidney, brain, and heart were assayed for degree of lipid peroxidation, reduced and oxidized glutathione (GSH and GSSG, respectively) content, and activities of the free-radical detoxifying enzymes catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase. Piperine treatment of normal rats enhanced hepatic GSSG concentration by 100% and decreased renal GSH concentration by 35% and renal glutathione reductase activity by 25% when compared to normal controls. All tissues from diabetic animals exhibited disturbances in antioxidant defense when compared with normal controls. Treatment with piperine reversed the diabetic effects on GSSG concentration in brain, on renal glutathione peroxidase and superoxide dismutase activities, and on cardiac glutathione reductase activity and lipid peroxidation. Piperine treatment did not reverse the effects of diabetes on hepatic GSH concentrations, lipid peroxidation, or glutathione peroxidase or catalase activities; on renal superoxide dismutase activity; or on cardiac glutathione peroxidase or catalase activities. These data indicate that subacute treatment with piperine for 14 days is only partially effective as an antioxidant therapy in diabetes.


Subject(s)
Alkaloids , Antioxidants/metabolism , Brain/metabolism , Diabetes Mellitus, Experimental/metabolism , Kidney/metabolism , Lipid Peroxidation/drug effects , Liver/metabolism , Myocardium/metabolism , Piperidines/pharmacology , Animals , Benzodioxoles , Brain/drug effects , Enzyme Inhibitors/pharmacology , Glutathione/metabolism , Glutathione Disulfide/metabolism , Glutathione Reductase/metabolism , Glutathione Transferase/metabolism , Heart/drug effects , Kidney/drug effects , Liver/drug effects , Male , Polyunsaturated Alkamides , Rats , Rats, Sprague-Dawley , Reference Values , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism
5.
J Biochem Mol Toxicol ; 14(4): 189-94, 2000.
Article in English | MEDLINE | ID: mdl-10789496

ABSTRACT

Diabetes mellitus and its complications are associated with elevated oxidative stress, leading to much interest in antioxidant compounds as possible therapeutic agents. Two new classes of antioxidant compounds, the pyrrolopyrimidines and the 21-aminosteroids, are known to inhibit lipid peroxidation and other biomolecular oxidation. We hypothesized that in the presence of excess oxidants or the impaired antioxidant defense seen in diabetes mellitus, administration of antioxidants such as these may reverse the effects of diabetes on antioxidant parameters. This study measured the effects of subchronic (14 day) treatment with a pyrrolopyrimidine (PNU-104067F) or a 21-aminosteroid (PNU-74389G) in normal and diabetic Sprague-Dawley rats. Activity levels of superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase, concentrations of oxidized and reduced glutathione, and lipid peroxidation were used as measures of antioxidant defense in liver, kidney, heart, and brain tissue. In normal rats, the only effect was a 43% increase in cardiac lipid peroxidation after treatment with PNU-104067F. In diabetic rats, the only reversals of the effects of diabetes were a 30% decrease in hepatic glutathione peroxidase activity after PNU-74389G treatment and a 33% increase in cardiac glutathione disulfide concentration after PNU-104067F treatment. In contrast to these effects, increased cardiac glutathione peroxidase and catalase activities, increased brain glutathione peroxidase activity, increased hepatic lipid peroxidation, decreased hepatic glutathione content, and decreased hepatic catalase activity were seen in diabetic rats, reflecting an exacerbation of the effects of diabetes.


Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Experimental/metabolism , Pregnatrienes/pharmacology , Pyrimidines/pharmacology , Pyrroles/pharmacology , Animals , Body Weight , Liver/metabolism , Male , Organ Size , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...